CoChat
Sign Up
Cited by 15Ovarian cancer diagnosis and treatmentIntraperitoneal and Appendiceal MalignanciesEndometrial and Cervical Cancer Treatments

Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient Outcomes

Open access
Skaznik-Wikiel, Malgorzata E., Lesnock, Jamie L., McBee, William C., Beriwal, Sushil, Zorn, Kristin K., Richard, Scott D., Krivak, Thomas C., Edwards, Robert P.·2012·International Journal of Gynecological Cancer
DOI 10.1097/igc.0b013e318234f833
Open this paper in CoChat — free account

Abstract

Objectives Three large randomized clinical trials have shown a survival benefit for patients treated with intraperitoneal (IP) compared with intravenous chemotherapy for advanced stage epithelial ovarian cancer (EOC). However, the use of IP chemotherapy in recurrent EOC is controversial. The purpose of this study was to determine outcomes, completion rates, and frequency of complications in patients with platinum-sensitive recurrent EOC treated with IP chemotherapy.Methods A retrospective, single-institution analysis of women who received IP chemotherapy for recurrent EOC from January 2003 to April 2010 was conducted. Study patients were identified from the Tumor Registry and office records. Demographic factors, stage, histology, surgical findings, cytoreduction status, and subsequent therapies were abstracted. Progression-free (PFS) and overall survival (OS) were estimated by Kaplan-Meier methods.Results Fifty-six women who received IP chemotherapy for their first EOC recurrence were identified. The mean age of patients was 56.7 years (range, 40-79 y). Fifty-five patients (98.3%) had previously completed at least 6 cycles of intravenous chemotherapy. Of all patients, 87.5% were initially diagnosed with advanced stage disease (stage IIA-IV). All patients underwent secondary cytoreduction at the time of IP port placement. Moreover, 67.9% of patients were considered optimally cytoreduced (<1 cm residual disease) at the end of the secondary debulking surgery. Forty-two patients (75%) were able to successfully complete at least 6 cycles of IP chemotherapy. Reasons for noncompletion were disease progression, allergic reaction, renal failure, pain, severe nausea and vomiting, death, and patient refusal. Six patients (10.7%) developed port complications including pain around port site, port malfunction, and port erosion into small bowel. Median PFS since the initiation of IP chemotherapy was 10.5 months (95% confidence interval, 7.5-16.4 months) and median OS was 51 months (95% confidence interval, 40.8-61.1 months).Conclusions Intraperitoneal chemotherapy is a feasible option for patients with recurrent EOC, with high completion rates, low frequency of complications, and acceptable PFS and OS.

Integrity signals

Registry

Crossref · 10.1097/igc.0b013e318234f833

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Partial systemic restriction of intraperitoneal administration resulted in reduced toxicity and treatment-related complications.

    “Furthermore, the partial systemic restriction of intraperitoneal administration resulted in reduced toxicity and treatment-related complications (44–46).”

    From CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy (2020) · cites this paper as [46]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Skaznik-Wikiel, M. E., Lesnock, J. L., McBee, W. C., Beriwal, S., Zorn, K. K., Richard, S. D., Krivak, T. C., & Edwards, R. P.
Affiliations
Magee-Womens Hospital (US)
ORCID
Venue
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Published
2012-02
Volume
22
Issue
2
Pages
232-237
ISSN
1048-891X (ISSN-L)
DOI
10.1097/igc.0b013e318234f833
OpenAlex
W2065371661
Cited by
15
References
26
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 1 · 2016: 1 · 2014: 2 · 2013: 1 · 2012: 1
FWCI
1.42
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Gynecological Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
intraperitoneal chemotherapy, recurrent epithelial ovarian cancer, platinum-sensitive ovarian cancer, port complications, secondary cytoreductive surgery, progression-free survival, overall survival, treatment feasibility
MeSH terms
Carcinoma, Ovarian Epithelial, Adenocarcinoma, Papillary, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Infusions, Parenteral, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Pennsylvania, Registries, Retrospective Studies, Survival Analysis, Treatment Outcome, Paclitaxel, Disease-Free Survival, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review